Navigation Links
Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
Date:5/20/2008

1 study in normal healthy volunteers is ongoing in which the Company is evaluating the pharmacokinetics, safety and tolerability of RDEA119, as well as its ability to inhibit inflammatory cytokines. Preliminary Phase 1 data have demonstrated that RDEA119 has a long half-life and favorable pharmacokinetic properties, allowing for once daily oral dosing. In addition, RDEA119 is currently in a Phase 1 study in advanced cancer patients. The doses being evaluated in the Phase 1 study in advanced cancer patients have achieved systemic exposure consistent with active doses in animal models of human tumors, without drug-related toxicity.

The presentation is available on the Company website (http://www.ardeabio.com/) under the title "RDEA119, a Potent and Highly Selective MEK Inhibitor Ameliorates Murine Colitis."

Corporate Update at Annual Stockholder Meeting

Ardea will provide a corporate update at its Annual Stockholder Meeting. The presentation is scheduled for Thursday, May 22nd, at 9:30 a.m. Pacific Time. To participate by telephone, please dial 877-440-5804 from the U.S. and Canada or +1-719-325-4854 for international callers. In addition, the live conference call is being webcast and can be accessed on the "News & Events" page of the Company's website at http://www.ardeabio.com. A replay will also be available on Ardea's website for 14 days and by telephone through May 31, 2008. For the telephonic replay, please dial 888-203-1112 in the U.S. and Canada or +1-719-457-0820 for international callers, and enter passcode 9342491 when prompted.

About RDEA119

RDEA119, a non-ATP competitive, highly-selective MEK inhibitor for the treatment of inflammatory diseases and cancer, is the Company's lead compound from its MEK inhibitor research and development program. RDEA119 has shown potential as a potent inhibitor of MEK, which is believed
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
2. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
3. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
4. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
11. Neurocrine Biosciences Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)...  Olympus, a precision technology leader in designing and ... other core businesses, announced today the opening of its ... MN. The new medical device research & ... company for continued long-term growth in the surgical sector. ... on April 27 and was attended by Mark ...
(Date:4/28/2015)... 28, 2015  Securities lawyers at Dunnam & ... ANGO ). Concerned ANGO investors who purchased between ... to contact securities attorney Hamilton Lindley by clicking ... 9, 2015, a quarterly loss of $4.3 million and ... year to a range of $356 million to $360 ...
(Date:4/28/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( http://www.oramed.com ... I am very excited to announce that we are on ... for oral insulin (ORMD-0801) and the treatment of type 2 ... coming weeks. This clinical trial will be our largest and most ... the company, literally putting us in a different place. ...
Breaking Medicine Technology:Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 3Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 4Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 2Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 3
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
(Date:4/28/2015)... 28, 2015 The popular all-natural supplement ... for their newly launched L-Style Revolution Program™, and collectively ... counting in just two short months. The customized ... exercise plan for men and women of all health ... loss and weight maintenance goals faster than traditional methods. ...
(Date:4/28/2015)... MSA Executive Search , an INTEGRATED ... that it has been retained to lead a nationwide ... for The Queen's Health Systems (QHS) located in ... & CEO Arthur A. Ushijima, the Executive Vice President ... the Queen’s Medical Center Punchbowl and West O’ahu sites, ...
(Date:4/28/2015)... PA (PRWEB) April 28, 2015 An ... Blair A. Jobe, MD, FACS , has launched ... esophageal tissue with extracellular matrix (ECM) can help patients ... form of esophageal cancer. , ECM is a complex ... cell attachment and migration and signals that guide cell ...
(Date:4/28/2015)... New and more complex medicines ... manufacturers, payers, pharmacists and patients. Now Specialty Pharmacy ... partnering with the National Association of Specialty Pharmacy ... to this developing field to better equip pharmacy ... , “This partnership creates a powerful platform for ...
(Date:4/28/2015)... Chicago, IL (PRWEB) April 28, 2015 ... enhance its research and healthcare services programs, the ... Orlando, Ph.D. Orlando comes to MDA from Fidelity ... oversaw funding of research projects in neurodegenerative diseases ... scientific conferences. Prior to her time at Fidelity, ...
Breaking Medicine News(10 mins):Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 3Health News:The Queen’s Health Systems Retains MSA Executive Search to Recruit Executive Vice President & Chief Operating Officer 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 3Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 4Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3
... , , , REDMOND, ... meeting that seeks solely to personally enlighten and transform the people ... annual meeting under the vision of Chairman and CEO Dwayne ... memory care communities, Aegis Living is in the business of taking ...
... , WASHINGTON , Jan. ... announced that it has filed a motion for immediate relief ... Georgia from the imminent and serious threat of ... late yesterday, seeks appointment of a monitor who will set ...
... online resources, coping tips , FRIDAY, Jan. 29 (HealthDay ... for 75 percent of adult cancer patients, according to ... , Breakthrough cancer pain refers to sudden, temporary flares ... is taking pain medication. , "We,re not talking about ...
... when caught early. But in a third of cases, ... when cure is much less likely. , Quicker identification ... mathematical model developed by researchers at the Ohio State ... Richard J. Solove Research Institute., The model uses information ...
... Association of Physicists in Medicine (AAPM) has issued a statement ... New York Times yesterday and earlier in the week that ... last decade involving people undergoing radiation therapy. While it ... the statement acknowledges their gravity. It reads in part: "The ...
... 2010 Investigators from the International Center for Biomedicine ... Center for Bioinformatics of the Universidad de Talca, have ... astemizole, may be suitable for use as PET (positron ... detection of Alzheimer,s Disease. The study is published in ...
Cached Medicine News:Health News:Aegis Living's CEO Transforms Business As Usual One Employee At a Time 2Health News:Aegis Living's CEO Transforms Business As Usual One Employee At a Time 3Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 2Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 3Health News:Justice Department Files for Immediate Relief Regarding Conditions in Georgia's Hospitals 4Health News:Three-Fourths of Cancer Patients Have Severe Flares of Pain 2Health News:Three-Fourths of Cancer Patients Have Severe Flares of Pain 3Health News:Curing more cervical cancer cases may be in the math 2Health News:AAPM statement on quality radiation therapy 2Health News:Promising new neuroimaging techniques for early detection of Alzheimer's disease 2
... continue the outstanding worldwide ... microscopes in medical and ... UIS infinity-corrected optics. The ... performance and even greater ...
... Coolscope operates with a simple click ... display. Direct the mouse cursor to ... image of the slide and the ... intuitive Graphic User Interface (GUI) enables ...
... Eclipse TS100 is an innovative ... This high quality tool complements ... and increased stability - Nikon ... vibration resistant design that greatly ...
Carbide drill bits, cutters, side cutting. Available in various sizes....
Medicine Products: